{"transactions":[{"id":1207882,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":82025,"kind":"person","name":"Beskrovnaya Oxana","position":1,"cik":"0001824542","reported_name":"Beskrovnaya Oxana","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2025-03-13T16:08:14.000Z","date":"2025-03-11","kind":"sale","planned":true,"acquired":false,"shares":2153,"price":11.38,"value":24501.14,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on December 10, 2021 and December 9, 2022. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a \"binding contract\" consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $11.25 to $11.48, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote of this Form 4."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 152,839 unvested RSUs."}],"balance_after":195840,"source":{"system":"sec-edgar","filing":"0000950170-25-038726","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1824542/000095017025038726/ownership.xml","form_type":"4"}},{"id":1217587,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":82025,"kind":"person","name":"Beskrovnaya Oxana","position":1,"cik":"0001824542","reported_name":"Beskrovnaya Oxana","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2025-03-07T16:04:13.000Z","date":"2025-03-05","kind":"sale","planned":true,"acquired":false,"shares":1094,"price":11.83,"value":12942.02,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on December 4, 2024. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a \"binding contract\" consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $11.73 to $11.94, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote of this Form 4."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 157,622 unvested RSUs."}],"balance_after":197993,"source":{"system":"sec-edgar","filing":"0000950170-25-035472","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1824542/000095017025035472/ownership.xml","form_type":"4"}},{"id":1246488,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":82025,"kind":"person","name":"Beskrovnaya Oxana","position":1,"cik":"0001824542","reported_name":"Beskrovnaya Oxana","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2025-02-25T17:09:59.000Z","date":"2025-02-18","kind":"sale","planned":true,"acquired":false,"shares":2598,"price":13.95,"value":36242.1,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"This transaction is being reported late due to an inadvertent administrative error."},{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on November 15, 2023. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a \"binding contract\" consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $13.95 to $14.05, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote of this Form 4."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"Includes 160,065 unvested RSUs."}],"balance_after":199087,"source":{"system":"sec-edgar","filing":"0000950170-25-026837","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1824542/000095017025026837/ownership.xml","form_type":"4"}},{"id":1335808,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":82025,"kind":"person","name":"Beskrovnaya Oxana","position":1,"cik":"0001824542","reported_name":"Beskrovnaya Oxana","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2024-12-11T20:41:31.000Z","date":"2024-12-11","kind":"sale","planned":true,"acquired":false,"shares":2334,"price":28.12,"value":65632.08,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on December 10, 2021 and December 9, 2022. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a \"binding contract\" consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $27.76 to $28.71, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote of this Form 4."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 165,922 unvested RSUs."}],"balance_after":201685,"source":{"system":"sec-edgar","filing":"0000950170-24-135571","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1824542/000095017024135571/ownership.xml","form_type":"4"}},{"id":1340577,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":82025,"kind":"person","name":"Beskrovnaya Oxana","position":1,"cik":"0001824542","reported_name":"Beskrovnaya Oxana","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock option (right to buy)","published_at":"2024-12-06T16:05:06.000Z","date":"2024-12-04","kind":"grant","planned":false,"acquired":true,"shares":62400,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"This option was granted on December 4, 2024. The shares underlying the option are scheduled to vest over four years in equal monthly installments through December 4, 2028."}],"balance_after":62400,"derivative":{"exercise_price":29.44,"expiration_date":"2034-12-03","underlying":"Common Stock","underlying_shares":62400},"source":{"system":"sec-edgar","filing":"0000950170-24-134070","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1824542/000095017024134070/ownership.xml","form_type":"4"}},{"id":1340576,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":82025,"kind":"person","name":"Beskrovnaya Oxana","position":1,"cik":"0001824542","reported_name":"Beskrovnaya Oxana","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2024-12-06T16:05:06.000Z","date":"2024-12-04","kind":"grant","planned":false,"acquired":true,"shares":27400,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Consists of shares of Common Stock issuable under 27,400 RSUs. Each RSU represents the right to receive one share of Common Stock upon vesting. These RSUs are scheduled to vest in full on December 4, 2025."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 170,705 unvested RSUs."}],"balance_after":204019,"source":{"system":"sec-edgar","filing":"0000950170-24-134070","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1824542/000095017024134070/ownership.xml","form_type":"4"}},{"id":1340575,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":82025,"kind":"person","name":"Beskrovnaya Oxana","position":1,"cik":"0001824542","reported_name":"Beskrovnaya Oxana","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2024-12-06T16:05:06.000Z","date":"2024-12-04","kind":"grant","planned":false,"acquired":true,"shares":39100,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Consists of shares of Common Stock issuable under 39,100 restricted stock units (\"RSUs\"). Each RSU represents the right to receive one share of Common Stock upon vesting. These RSUs are scheduled to vest in equal quarterly installments over four years with the first installment vesting on March 4, 2025."}],"balance_after":176619,"source":{"system":"sec-edgar","filing":"0000950170-24-134070","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1824542/000095017024134070/ownership.xml","form_type":"4"}},{"id":1361924,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":82025,"kind":"person","name":"Beskrovnaya Oxana","position":1,"cik":"0001824542","reported_name":"Beskrovnaya Oxana","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2024-11-18T16:28:17.000Z","date":"2024-11-18","kind":"sale","planned":true,"acquired":false,"shares":2856,"price":28.2,"value":80539.2,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on November 15, 2023. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a \"binding contract\" consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $28.00 to $28.60, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote of this Form 4."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 104,205 unvested RSUs."}],"balance_after":137519,"source":{"system":"sec-edgar","filing":"0000950170-24-127989","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1824542/000095017024127989/ownership.xml","form_type":"4"}},{"id":1402493,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":82025,"kind":"person","name":"Beskrovnaya Oxana","position":1,"cik":"0001824542","reported_name":"Beskrovnaya Oxana","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2024-09-19T16:51:20.000Z","date":"2024-09-18","kind":"sale","planned":true,"acquired":false,"shares":2339,"price":34.55,"value":80812.45,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on September 17, 2020. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a \"binding contract\" consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $34.35 to $34.70, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote of this Form 4."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 110,062 unvested RSUs."}],"balance_after":140375,"source":{"system":"sec-edgar","filing":"0000950170-24-108151","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1824542/000095017024108151/ownership.xml","form_type":"4"}},{"id":1409838,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":82025,"kind":"person","name":"Beskrovnaya Oxana","position":1,"cik":"0001824542","reported_name":"Beskrovnaya Oxana","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2024-09-11T16:13:44.000Z","date":"2024-09-11","kind":"sale","planned":true,"acquired":false,"shares":2161,"price":31.89,"value":68914.29,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on December 10, 2021 and December 9, 2022. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a \"binding contract\" consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $31.59 to $32.15, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote of this Form 4."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 114,885 unvested RSUs."}],"balance_after":142714,"source":{"system":"sec-edgar","filing":"0000950170-24-105517","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1824542/000095017024105517/ownership.xml","form_type":"4"}},{"id":1427813,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":82025,"kind":"person","name":"Beskrovnaya Oxana","position":1,"cik":"0001824542","reported_name":"Beskrovnaya Oxana","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2024-08-20T16:26:33.000Z","date":"2024-08-19","kind":"sale","planned":true,"acquired":false,"shares":296,"price":46,"value":13616.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on November 15, 2023. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a \"binding contract\" consistent with the affirmative defense to liability under Rule 10b5-1 that was entered into on January 25, 2024 and the sale does not represent a discretionary trade by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $45.53 to $46.45, inclusive."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"Includes 119,668 unvested RSUs."}],"balance_after":144875,"source":{"system":"sec-edgar","filing":"0000950170-24-099122","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1824542/000095017024099122/ownership.xml","form_type":"4"}},{"id":1427812,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":82025,"kind":"person","name":"Beskrovnaya Oxana","position":1,"cik":"0001824542","reported_name":"Beskrovnaya Oxana","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2024-08-20T16:26:33.000Z","date":"2024-08-19","kind":"sale","planned":true,"acquired":false,"shares":2340,"price":45.01,"value":105323.4,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on November 15, 2023. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a \"binding contract\" consistent with the affirmative defense to liability under Rule 10b5-1 that was entered into on January 25, 2024 and the sale does not represent a discretionary trade by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $44.51 to $45.48, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in the footnotes of this Form 4."}],"balance_after":145171,"source":{"system":"sec-edgar","filing":"0000950170-24-099122","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1824542/000095017024099122/ownership.xml","form_type":"4"}},{"id":1483650,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":82025,"kind":"person","name":"Beskrovnaya Oxana","position":1,"cik":"0001824542","reported_name":"Beskrovnaya Oxana","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2024-06-11T19:42:47.000Z","date":"2024-06-11","kind":"sale","planned":false,"acquired":false,"shares":2136,"price":31.34,"value":66942.24,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on December 10, 2021 and December 9, 2022. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a \"binding contract\" consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $31.00 to $31.52, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 125,525 unvested RSUs."}],"balance_after":147511,"source":{"system":"sec-edgar","filing":"0000950170-24-072170","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1824542/000095017024072170/ownership.xml","form_type":"4"}},{"id":1505583,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":82025,"kind":"person","name":"Beskrovnaya Oxana","position":1,"cik":"0001824542","reported_name":"Beskrovnaya Oxana","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock option (right to buy)","published_at":"2024-05-22T21:01:04.000Z","date":"2024-05-20","kind":"exercise","planned":true,"acquired":false,"shares":30426,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The option was granted on January 6, 2020. The shares underlying the option vest over four years, with 25% of the shares vesting on January 27, 2021 and the remaining shares vesting in equal quarterly installments thereafter."}],"balance_after":0,"derivative":{"exercise_price":1.03,"expiration_date":"2030-01-05","underlying":"Common Stock","underlying_shares":30426},"source":{"system":"sec-edgar","filing":"0000950170-24-063737","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1824542/000095017024063737/ownership.xml","form_type":"4"}},{"id":1505582,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":82025,"kind":"person","name":"Beskrovnaya Oxana","position":1,"cik":"0001824542","reported_name":"Beskrovnaya Oxana","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2024-05-22T21:01:04.000Z","date":"2024-05-20","kind":"sale","planned":true,"acquired":false,"shares":1145,"price":34.08,"value":39021.6,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 30, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $34.02 to $34.16, inclusive."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F5","text":"Includes 130,308 unvested RSUs."}],"balance_after":149647,"source":{"system":"sec-edgar","filing":"0000950170-24-063737","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1824542/000095017024063737/ownership.xml","form_type":"4"}},{"id":1505581,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":82025,"kind":"person","name":"Beskrovnaya Oxana","position":1,"cik":"0001824542","reported_name":"Beskrovnaya Oxana","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2024-05-22T21:01:04.000Z","date":"2024-05-20","kind":"sale","planned":true,"acquired":false,"shares":12147,"price":33.51,"value":407045.97,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 30, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $33.01 to $34.01, inclusive."}],"balance_after":150792,"source":{"system":"sec-edgar","filing":"0000950170-24-063737","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1824542/000095017024063737/ownership.xml","form_type":"4"}},{"id":1505580,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":82025,"kind":"person","name":"Beskrovnaya Oxana","position":1,"cik":"0001824542","reported_name":"Beskrovnaya Oxana","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2024-05-22T21:01:04.000Z","date":"2024-05-20","kind":"sale","planned":true,"acquired":false,"shares":17134,"price":32.49,"value":556683.66,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 30, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $32.00 to $33.00, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in the footnotes of this Form 4."}],"balance_after":162939,"source":{"system":"sec-edgar","filing":"0000950170-24-063737","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1824542/000095017024063737/ownership.xml","form_type":"4"}},{"id":1505579,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":82025,"kind":"person","name":"Beskrovnaya Oxana","position":1,"cik":"0001824542","reported_name":"Beskrovnaya Oxana","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2024-05-22T21:01:04.000Z","date":"2024-05-20","kind":"exercise","planned":true,"acquired":true,"shares":30426,"price":1.03,"value":31338.78,"ownership":{"direct":true},"balance_after":180073,"source":{"system":"sec-edgar","filing":"0000950170-24-063737","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1824542/000095017024063737/ownership.xml","form_type":"4"}},{"id":1511674,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":82025,"kind":"person","name":"Beskrovnaya Oxana","position":1,"cik":"0001824542","reported_name":"Beskrovnaya Oxana","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2024-05-17T21:07:27.000Z","date":"2024-05-16","kind":"sale","planned":true,"acquired":false,"shares":483,"price":28.59,"value":13808.97,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on November 15, 2023. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a \"binding contract\" consistent with the affirmative defense to liability under Rule 10b5-1 that was entered into on January 25, 2024 and the sale does not represent a discretionary trade by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $28.51 to $28.70, inclusive."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"Includes 130,308 unvested RSUs."}],"balance_after":149647,"source":{"system":"sec-edgar","filing":"0000950170-24-062080","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1824542/000095017024062080/ownership.xml","form_type":"4"}},{"id":1511673,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":82025,"kind":"person","name":"Beskrovnaya Oxana","position":1,"cik":"0001824542","reported_name":"Beskrovnaya Oxana","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2024-05-17T21:07:27.000Z","date":"2024-05-16","kind":"sale","planned":true,"acquired":false,"shares":2222,"price":28.2,"value":62660.4,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on November 15, 2023. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a \"binding contract\" consistent with the affirmative defense to liability under Rule 10b5-1 that was entered into on January 25, 2024 and the sale does not represent a discretionary trade by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $27.50 to $28.50, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in the footnotes of this Form 4."}],"balance_after":150130,"source":{"system":"sec-edgar","filing":"0000950170-24-062080","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1824542/000095017024062080/ownership.xml","form_type":"4"}},{"id":1581444,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":82025,"kind":"person","name":"Beskrovnaya Oxana","position":1,"cik":"0001824542","reported_name":"Beskrovnaya Oxana","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2024-03-12T21:42:33.000Z","date":"2024-03-11","kind":"sale","planned":true,"acquired":false,"shares":2081,"price":25.7,"value":53481.7,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on December 10, 2021 and December 9, 2022. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a \"binding contract\" consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $25.50 to $26.09, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 136,165 unvested RSUs."}],"balance_after":152352,"source":{"system":"sec-edgar","filing":"0000950170-24-030443","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1824542/000095017024030443/ownership.xml","form_type":"4"}},{"id":1584382,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":82025,"kind":"person","name":"Beskrovnaya Oxana","position":1,"cik":"0001824542","reported_name":"Beskrovnaya Oxana","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2024-03-11T21:56:46.000Z","date":"2024-03-07","kind":"sale","planned":true,"acquired":false,"shares":2373,"price":25.85,"value":61342.05,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on November 15, 2023. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a \"binding contract\" consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $25.84 to $26.33, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 140,948 unvested RSUs."}],"balance_after":154433,"source":{"system":"sec-edgar","filing":"0000950170-24-029615","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1824542/000095017024029615/ownership.xml","form_type":"4"}},{"id":1688123,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":82025,"kind":"person","name":"Beskrovnaya Oxana","position":1,"cik":"0001824542","reported_name":"Beskrovnaya Oxana","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock option (right to buy)","published_at":"2024-01-04T21:48:23.000Z","date":"2023-01-04","kind":"exercise","planned":true,"acquired":false,"shares":22674,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"The option was granted on January 6, 2020. The shares underlying the option vest over four years, with 25% of the shares vesting on January 27, 2021 and the remaining shares vesting in equal quarterly installments thereafter."}],"balance_after":30426,"derivative":{"exercise_price":1.03,"expiration_date":"2030-01-05","underlying":"Common Stock","underlying_shares":22674},"source":{"system":"sec-edgar","filing":"0000950170-24-002279","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1824542/000095017024002279/ownership.xml","form_type":"4"}},{"id":1688122,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":82025,"kind":"person","name":"Beskrovnaya Oxana","position":1,"cik":"0001824542","reported_name":"Beskrovnaya Oxana","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock option (right to buy)","published_at":"2024-01-04T21:48:23.000Z","date":"2024-01-03","kind":"exercise","planned":true,"acquired":false,"shares":45326,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"The option was granted on January 6, 2020. The shares underlying the option vest over four years, with 25% of the shares vesting on January 27, 2021 and the remaining shares vesting in equal quarterly installments thereafter."}],"balance_after":53100,"derivative":{"exercise_price":1.03,"expiration_date":"2030-01-05","underlying":"Common Stock","underlying_shares":45326},"source":{"system":"sec-edgar","filing":"0000950170-24-002279","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1824542/000095017024002279/ownership.xml","form_type":"4"}},{"id":1688121,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":82025,"kind":"person","name":"Beskrovnaya Oxana","position":1,"cik":"0001824542","reported_name":"Beskrovnaya Oxana","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2024-01-04T21:48:23.000Z","date":"2024-01-04","kind":"sale","planned":true,"acquired":false,"shares":42453,"price":18.13,"value":769672.89,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 30, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $18.00 to $18.45, inclusive."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes 146,805 unvested RSUs."}],"balance_after":156806,"source":{"system":"sec-edgar","filing":"0000950170-24-002279","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1824542/000095017024002279/ownership.xml","form_type":"4"}},{"id":1688120,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":82025,"kind":"person","name":"Beskrovnaya Oxana","position":1,"cik":"0001824542","reported_name":"Beskrovnaya Oxana","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2024-01-04T21:48:23.000Z","date":"2024-01-04","kind":"exercise","planned":true,"acquired":true,"shares":22674,"price":1.03,"value":23354.22,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes 146,805 unvested RSUs."}],"balance_after":199259,"source":{"system":"sec-edgar","filing":"0000950170-24-002279","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1824542/000095017024002279/ownership.xml","form_type":"4"}},{"id":1688119,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":82025,"kind":"person","name":"Beskrovnaya Oxana","position":1,"cik":"0001824542","reported_name":"Beskrovnaya Oxana","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2024-01-04T21:48:23.000Z","date":"2024-01-03","kind":"sale","planned":true,"acquired":false,"shares":5361,"price":20.5,"value":109900.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 30, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $20.50 to $20.56, inclusive."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes 146,805 unvested RSUs."}],"balance_after":176585,"source":{"system":"sec-edgar","filing":"0000950170-24-002279","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1824542/000095017024002279/ownership.xml","form_type":"4"}},{"id":1688118,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":82025,"kind":"person","name":"Beskrovnaya Oxana","position":1,"cik":"0001824542","reported_name":"Beskrovnaya Oxana","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2024-01-04T21:48:23.000Z","date":"2024-01-03","kind":"sale","planned":true,"acquired":false,"shares":24583,"price":19.05,"value":468306.15,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 30, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $19.00 to $19.25, inclusive."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes 146,805 unvested RSUs."}],"balance_after":181946,"source":{"system":"sec-edgar","filing":"0000950170-24-002279","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1824542/000095017024002279/ownership.xml","form_type":"4"}},{"id":1688117,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":82025,"kind":"person","name":"Beskrovnaya Oxana","position":1,"cik":"0001824542","reported_name":"Beskrovnaya Oxana","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2024-01-04T21:48:23.000Z","date":"2024-01-03","kind":"sale","planned":true,"acquired":false,"shares":15382,"price":18.34,"value":282105.88,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 30, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $18.00 to $18.50, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in the footnotes of this Form 4."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes 146,805 unvested RSUs."}],"balance_after":206529,"source":{"system":"sec-edgar","filing":"0000950170-24-002279","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1824542/000095017024002279/ownership.xml","form_type":"4"}},{"id":1688116,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":82025,"kind":"person","name":"Beskrovnaya Oxana","position":1,"cik":"0001824542","reported_name":"Beskrovnaya Oxana","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2024-01-04T21:48:23.000Z","date":"2024-01-03","kind":"exercise","planned":true,"acquired":true,"shares":45326,"price":1.03,"value":46685.78,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes 146,805 unvested RSUs."}],"balance_after":221911,"source":{"system":"sec-edgar","filing":"0000950170-24-002279","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1824542/000095017024002279/ownership.xml","form_type":"4"}},{"id":1714467,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":82025,"kind":"person","name":"Beskrovnaya Oxana","position":1,"cik":"0001824542","reported_name":"Beskrovnaya Oxana","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2023-12-12T17:32:28.000Z","date":"2023-12-11","kind":"sale","planned":false,"acquired":false,"shares":1467,"price":10.72,"value":15726.24,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on December 10, 2021 and December 9, 2022. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a \"binding contract\" consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $10.72 to $10.81, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 146,805 unvested RSUs."}],"balance_after":176585,"source":{"system":"sec-edgar","filing":"0001209191-23-058326","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1824542/000120919123058326/doc4.xml","form_type":"4"}},{"id":1739257,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":82025,"kind":"person","name":"Beskrovnaya Oxana","position":1,"cik":"0001824542","reported_name":"Beskrovnaya Oxana","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Option (right to buy)","published_at":"2023-11-16T16:23:49.000Z","date":"2023-11-15","kind":"grant","planned":false,"acquired":true,"shares":36495,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This option was granted on November 15, 2023. The shares underlying the option are scheduled to vest over four years in equal monthly installments through November 15, 2027."}],"balance_after":36495,"derivative":{"exercise_price":10.88,"expiration_date":"2033-11-14","underlying":"Common Stock","underlying_shares":36495},"source":{"system":"sec-edgar","filing":"0001209191-23-055521","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1824542/000120919123055521/doc4.xml","form_type":"4"}},{"id":1739256,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":82025,"kind":"person","name":"Beskrovnaya Oxana","position":1,"cik":"0001824542","reported_name":"Beskrovnaya Oxana","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2023-11-16T16:23:49.000Z","date":"2023-11-15","kind":"grant","planned":false,"acquired":true,"shares":93718,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Consists of shares of Common Stock issuable under 93,718 restricted stock units (\"RSUs\"). Each RSU represents the right to receive one share of Common Stock upon vesting. These RSUs are scheduled to vest in equal quarterly installments over four years with the first installment vesting on February 15, 2024."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 151,588 unvested RSUs."}],"balance_after":178052,"source":{"system":"sec-edgar","filing":"0001209191-23-055521","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1824542/000120919123055521/doc4.xml","form_type":"4"}},{"id":1776302,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":82025,"kind":"person","name":"Beskrovnaya Oxana","position":1,"cik":"0001824542","reported_name":"Beskrovnaya Oxana","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2023-09-20T16:47:17.000Z","date":"2023-09-18","kind":"sale","planned":false,"acquired":false,"shares":1436,"price":9.41,"value":13512.76,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on September 17, 2020. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a \"binding contract\" consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the Reporting Person."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 57,870 unvested RSUs."}],"balance_after":84334,"source":{"system":"sec-edgar","filing":"0001209191-23-050168","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1824542/000120919123050168/doc4.xml","form_type":"4"}},{"id":1782176,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":82025,"kind":"person","name":"Beskrovnaya Oxana","position":1,"cik":"0001824542","reported_name":"Beskrovnaya Oxana","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2023-09-13T19:50:06.000Z","date":"2023-09-12","kind":"sale","planned":false,"acquired":false,"shares":1484,"price":10.41,"value":15448.44,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on December 10, 2021 and December 9, 2022. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a \"binding contract\" consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $10.08 to $10.43, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 62,692 unvested RSUs."}],"balance_after":85770,"source":{"system":"sec-edgar","filing":"0001209191-23-049356","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1824542/000120919123049356/doc4.xml","form_type":"4"}},{"id":1856026,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":82025,"kind":"person","name":"Beskrovnaya Oxana","position":1,"cik":"0001824542","reported_name":"Beskrovnaya Oxana","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2023-06-14T18:39:34.000Z","date":"2023-06-13","kind":"sale","planned":false,"acquired":false,"shares":1475,"price":12.43,"value":18334.25,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on December 10, 2021 and December 9, 2022. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a \"binding contract\" consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the Reporting Person."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 67,475 unvested RSUs."}],"balance_after":87254,"source":{"system":"sec-edgar","filing":"0001209191-23-037163","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1824542/000120919123037163/doc4.xml","form_type":"4"}},{"id":1952361,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":82025,"kind":"person","name":"Beskrovnaya Oxana","position":1,"cik":"0001824542","reported_name":"Beskrovnaya Oxana","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2023-03-15T17:48:38.000Z","date":"2023-03-14","kind":"sale","acquired":false,"shares":1416,"price":13.33,"value":18875.28,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on December 10, 2021 and December 9, 2022. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a \"binding contract\" consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the Reporting Person."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 72,258 unvested RSUs."}],"balance_after":88729,"source":{"system":"sec-edgar","filing":"0001209191-23-018977","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1824542/000120919123018977/doc4.xml","form_type":"4"}},{"id":2088169,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":82025,"kind":"person","name":"Beskrovnaya Oxana","position":1,"cik":"0001824542","reported_name":"Beskrovnaya Oxana","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Option (right to buy)","published_at":"2022-12-13T17:03:32.000Z","date":"2022-12-09","kind":"grant","acquired":true,"shares":63000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"This option was granted on December 9, 2022. The shares underlying the option are scheduled to vest over four years in equal monthly installments through December 10, 2026."}],"balance_after":63000,"derivative":{"exercise_price":10.72,"expiration_date":"2032-12-08","underlying":"Common Stock","underlying_shares":63000},"source":{"system":"sec-edgar","filing":"0001209191-22-060964","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1824542/000120919122060964/doc4.xml","form_type":"4"}},{"id":2088168,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":82025,"kind":"person","name":"Beskrovnaya Oxana","position":1,"cik":"0001824542","reported_name":"Beskrovnaya Oxana","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2022-12-13T17:03:32.000Z","date":"2022-12-12","kind":"sale","acquired":false,"shares":680,"price":10.87,"value":7391.6,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on December 10, 2021. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a \"binding contract\" consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the Reporting Person."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"Includes 77,041 unvested RSUs."}],"balance_after":90145,"source":{"system":"sec-edgar","filing":"0001209191-22-060964","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1824542/000120919122060964/doc4.xml","form_type":"4"}},{"id":2088167,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":82025,"kind":"person","name":"Beskrovnaya Oxana","position":1,"cik":"0001824542","reported_name":"Beskrovnaya Oxana","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2022-12-13T17:03:32.000Z","date":"2022-12-09","kind":"grant","acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Consists of shares of Common Stock issuable under 40,000 restricted stock units (\"RSUs\"). Each RSU represents the right to receive one share of Common Stock upon vesting. These RSUs are scheduled to vest in equal quarterly installments over four years with the first installment vesting on March 10, 2023."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 79,323 unvested RSUs."}],"balance_after":90825,"source":{"system":"sec-edgar","filing":"0001209191-22-060964","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1824542/000120919122060964/doc4.xml","form_type":"4"}},{"id":2153528,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":82025,"kind":"person","name":"Beskrovnaya Oxana","position":1,"cik":"0001824542","reported_name":"Beskrovnaya Oxana","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2022-09-21T16:07:28.000Z","date":"2022-09-20","kind":"disposition_to_issuer","acquired":false,"shares":1413,"price":13.7,"value":19358.1,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on September 17, 2020. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a \"binding contract\" consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price that represents the price of all shares sold by a broker on September 20, 2022 to satisfy tax withholding obligations. These shares were sold in multiple transactions at prices within the range of $13.70 to $13.78, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range(s) set forth in this footnote of this Form 4."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 39,323 unvested RSUs."}],"balance_after":50825,"source":{"system":"sec-edgar","filing":"0001209191-22-050881","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1824542/000120919122050881/doc4.xml","form_type":"4"}},{"id":2158512,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":82025,"kind":"person","name":"Beskrovnaya Oxana","position":1,"cik":"0001824542","reported_name":"Beskrovnaya Oxana","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2022-09-15T17:24:57.000Z","date":"2022-09-15","kind":"disposition_to_issuer","acquired":false,"shares":712,"price":14.05,"value":10003.6,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on December 10, 2021. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a \"binding contract\" consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price that represents the price of all shares sold by a broker on September 15, 2022 to satisfy tax withholding obligations. These shares were sold in multiple transactions at prices within the range of $14.05 to $14.20, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range(s) set forth in this footnote of this Form 4."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 44,145 unvested RSUs."}],"balance_after":52238,"source":{"system":"sec-edgar","filing":"0001209191-22-050117","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1824542/000120919122050117/doc4.xml","form_type":"4"}},{"id":2212184,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":82025,"kind":"person","name":"Beskrovnaya Oxana","position":1,"cik":"0001824542","reported_name":"Beskrovnaya Oxana","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Option (right to buy)","published_at":"2022-07-06T18:17:22.000Z","date":"2022-07-05","kind":"grant","acquired":true,"shares":23477,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option was granted on July 31, 2020, with 100% of the option to vest upon the clearance date of an Investigational New Drug (IND) application submitted to the U.S. Food and Drug Administration (FDA) by the Company with respect to one of its product candidates. On July 5, 2022, in connection with the clearance by the FDA of the Company's IND application for DYNE-251, the Compensation Committee determined that the performance condition had been achieved."}],"balance_after":23477,"derivative":{"exercise_price":5.54,"expiration_date":"2030-07-30","underlying":"Common Stock","underlying_shares":23477},"source":{"system":"sec-edgar","filing":"0001209191-22-041328","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1824542/000120919122041328/doc4.xml","form_type":"4"}},{"id":2231587,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":82025,"kind":"person","name":"Beskrovnaya Oxana","position":1,"cik":"0001824542","reported_name":"Beskrovnaya Oxana","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2022-06-15T20:02:05.000Z","date":"2022-06-14","kind":"disposition_to_issuer","acquired":false,"shares":726,"price":4.95,"value":3593.7,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on December 10, 2021. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a \"binding contract\" consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the Reporting Person."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 46,427 unvested RSUs."}],"balance_after":52950,"source":{"system":"sec-edgar","filing":"0001209191-22-037142","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1824542/000120919122037142/doc4.xml","form_type":"4"}},{"id":2335688,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":82025,"kind":"person","name":"Beskrovnaya Oxana","position":1,"cik":"0001824542","reported_name":"Beskrovnaya Oxana","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2022-03-14T17:06:23.000Z","date":"2022-03-11","kind":"sale","acquired":false,"shares":693,"price":8.73,"value":6049.89,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on December 10, 2021. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a \"binding contract\" consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price that represents the price of all shares sold by a broker on March 11, 2022 to satisfy tax withholding obligations. These shares were sold in multiple transactions at prices within the range of $8.65 to $8.73, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range(s) set forth in this footnote of this Form 4."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 48,709 unvested RSUs."}],"balance_after":53676,"source":{"system":"sec-edgar","filing":"0001209191-22-018530","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1824542/000120919122018530/doc4.xml","form_type":"4"}},{"id":2473665,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":82025,"kind":"person","name":"Beskrovnaya Oxana","position":1,"cik":"0001824542","reported_name":"Beskrovnaya Oxana","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Option (right to buy)","published_at":"2021-12-14T16:19:27.000Z","date":"2021-12-10","kind":"grant","acquired":true,"shares":54786,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This option was granted on December 10, 2021. The shares underlying the option are scheduled to vest over four years in equal monthly installments through December 10, 2025."}],"balance_after":54786,"derivative":{"exercise_price":13.12,"expiration_date":"2031-12-09","underlying":"Common Stock","underlying_shares":54786},"source":{"system":"sec-edgar","filing":"0001209191-21-069418","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1824542/000120919121069418/doc4.xml","form_type":"4"}},{"id":2473664,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":82025,"kind":"person","name":"Beskrovnaya Oxana","position":1,"cik":"0001824542","reported_name":"Beskrovnaya Oxana","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2021-12-14T16:19:27.000Z","date":"2021-12-10","kind":"grant","acquired":true,"shares":36524,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Consists of shares of Common Stock issuable under 36,524 restricted stock units (\"RSUs\"). Each RSU represents the right to receive one share of Common Stock upon vesting. These RSUs are scheduled to vest in equal quarterly installments over four years with the first installment vesting on March 10, 2022."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 50,991 unvested RSUs. Each unvested RSU represents the right to receive one share of Common Stock upon vesting."}],"balance_after":54369,"source":{"system":"sec-edgar","filing":"0001209191-21-069418","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1824542/000120919121069418/doc4.xml","form_type":"4"}},{"id":2562156,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":82025,"kind":"person","name":"Beskrovnaya Oxana","position":1,"cik":"0001824542","reported_name":"Beskrovnaya Oxana","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2021-09-22T20:01:58.000Z","date":"2021-09-21","kind":"sale","acquired":false,"shares":827,"price":16.11,"value":13322.97,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on September 17, 2020. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a \"binding contract\" consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price that represents the price of all shares sold by a broker on September 21, 2021 on behalf of a group of employees of the issuer to satisfy tax withholding obligations. These shares were sold in multiple transactions at prices within the range of $15.87 to $16.36, inclusive."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 14,467 unvested RSUs."}],"balance_after":17845,"source":{"system":"sec-edgar","filing":"0001209191-21-057323","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1824542/000120919121057323/doc4.xml","form_type":"4"}},{"id":2562155,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":82025,"kind":"person","name":"Beskrovnaya Oxana","position":1,"cik":"0001824542","reported_name":"Beskrovnaya Oxana","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2021-09-22T20:01:58.000Z","date":"2021-09-20","kind":"sale","acquired":false,"shares":617,"price":15.61,"value":9631.37,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on September 17, 2020. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a \"binding contract\" consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price that represents the price of all shares sold by a broker on September 20, 2021 on behalf of a group of employees of the issuer to satisfy tax withholding obligations. These shares were sold in multiple transactions at prices within the range of $15.22 to $16.01, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range(s) set forth in footnote (2) and (4) of this Form 4."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 14,467 unvested RSUs."}],"balance_after":18672,"source":{"system":"sec-edgar","filing":"0001209191-21-057323","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1824542/000120919121057323/doc4.xml","form_type":"4"}},{"id":2686964,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":82025,"kind":"person","name":"Beskrovnaya Oxana","position":1,"cik":"0001824542","reported_name":"Beskrovnaya Oxana","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Option (right to buy)","published_at":"2021-06-02T18:41:29.000Z","date":"2021-06-02","kind":"grant","acquired":true,"shares":110000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on June 2, 2021. The shares underlying the option are scheduled to vest over four years, with 25% of the shares vesting on June 2, 2022 and the remaining shares vesting in equal quarterly installments thereafter."}],"balance_after":110000,"derivative":{"exercise_price":19.05,"expiration_date":"2031-06-01","underlying":"Common Stock","underlying_shares":110000},"source":{"system":"sec-edgar","filing":"0000899243-21-021642","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1824542/000089924321021642/doc4.xml","form_type":"4"}},{"id":3027155,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":82025,"kind":"person","name":"Beskrovnaya Oxana","position":1,"cik":"0001824542","reported_name":"Beskrovnaya Oxana","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (right to buy)","published_at":"2020-09-18T17:13:40.000Z","date":"2020-09-16","kind":"grant","acquired":true,"shares":59857,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option was granted on September 16, 2020. The shares underlying the option are scheduled to vest over four years in equal monthly installments through September 16, 2024."}],"balance_after":59857,"derivative":{"exercise_price":19,"expiration_date":"2030-09-15","underlying":"Common Stock","underlying_shares":59857},"source":{"system":"sec-edgar","filing":"0000899243-20-025741","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1824542/000089924320025741/doc4.xml","form_type":"4"}},{"id":3027154,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":82025,"kind":"person","name":"Beskrovnaya Oxana","position":1,"cik":"0001824542","reported_name":"Beskrovnaya Oxana","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2020-09-18T17:13:40.000Z","date":"2020-09-17","kind":"grant","acquired":true,"shares":19289,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Consists of shares of Common Stock issuable under 19,289 restricted stock units (\"RSUs\"). Each RSU represents the right to receive one share of Common Stock upon vesting. These RSUs are scheduled to vest in equal annual installments over four years with the first installment vesting on September 17, 2021."}],"balance_after":19289,"source":{"system":"sec-edgar","filing":"0000899243-20-025741","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1824542/000089924320025741/doc4.xml","form_type":"4"}}]}